Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer.
Muralidhar, Vinayak; Catalano, Paul J; Reznor, Gally; Mahal, Brandon A; Choueiri, Toni K; Sweeney, Christopher J; Martin, Neil E; Beard, Clair J; Chen, Yu-Wei; Nezolosky, Michelle D; Hoffman, Karen E; Feng, Felix Y; Trinh, Quoc-Dien; Nguyen, Paul L.
J Natl Compr Canc Netw
; 14(4): 421-8, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27059190
Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.
Genetics and biology of prostate cancer.
Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.
Primary cryotherapy for localised or locally advanced prostate cancer.
Outcomes of treatment in men with prostate cancer at the cancer centre Bahamas.
Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
Obesity and prostate cancer.
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.